Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ga-68-PSMA-11 PET in preprostatectomy prostate cancer
NCT02919111Phase 3Completed
- Sponsor
- University of California, San Francisco
- Start
- Sep 2016
- Primary completion
- Dec 2019
- Modality
- Peptide-Drug Conjugates
- Countries
- 1
01
Overview
Phase 3, open-label trial of gallium ga-68 gozetotide in prostate cancer (PCa), sponsored by University of California, San Francisco. Primary endpoint: Sensitivity of PSMA PET for the Detection of Regional Nodal Metastases Compared to Pathology at Radical Prostatectomy at 1 year. Started Sep 2016; status: completed.
02
Drugs
gallium ga-68 gozetotide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02919111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02919111.